Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Louise Verrall from Lucid Group wins Communiqué 2016 Award for Emerging Leader in Healthcare Communications

From her first degree to her current position as Business Unit Director, Louise has developed a passion for science, education, psychology and entrepreneurialism. She is driven to make a difference...

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

The winning programme - Treating beyond symptoms in IBD: The Steroid Assessment Tool. Our approach to medical education is really helping to improve patient outcomes and change lives.

Lucid Group shines at the Communiqué Awards

Lucid Group’s commitment to be a leader in medical education was recognised at the Communiqué Awards 2016 in London last night, where the agency received three awards, including being highly...

Developing Medical Education That Advances Patient Outcomes

As pressure mounts on the pharmaceutical industry to demonstrate a tangible and positive impact on patients’ lives, understanding barriers to specific clinician behaviours is key to achieving measurable change in...

Future-proofing with a comprehensive talent development strategy

Lucid Group is an award-winning group of specialist medical education companies. Over the years, Lucid has developed a strong culture of empowerment, thought-leadership, entrepreneurship and passion to improve outcomes for...

Lucid reach the shortlist for Communiqué 2016 in SIX categories

Lucid Group are celebrating the news that for the first time they have been shortlisted in six different categories at this year’s Communiqué awards.  The categories are:Excellence in Communications of...

Lucid Co-founder and COO discusses the changing landscape of healthcare communications

In May’s issue, Jan Steele (Lucid co-founder and COO) talks to PME about the importance of demonstrating value with medical education via validated improvements in patient outcomes. Jan explains that...

New talent blooms at Lucid Group

Spring has most definitely sprung at Lucid Group as they welcome three new employees to their team. Laura Cunliffe joins as a Senior Account Manager at Leading Edge and will...

The art of changing behaviour with virtual technology

In April’s issue of PME, Ella Nuttall (Health Psychology Specialist at Lucid Group) explains how changing behaviour requires a combination of science and art. She outlines how the impact of...

Lucid CEO discusses the importance of company culture

In April’s Smart Thinking blog on pmlive.com, Dennis O’Brien (Lucid CEO) discusses company culture and how individual contribution is everything.Dennis explains that, despite organisations being obsessed with meeting financial targets every...